The non-hodgkin lymphoma condition center is a comprehensive resource for clinical news and expert insights on non-hodgkin lymphoma. Read more at OncLive.
May 16th 2024
Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.
May 15th 2024
The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.
May 7th 2024
Treatment with loncastuximab tesirine yielded high response rates in patients with relapsed or refractory marginal zone lymphoma.
May 6th 2024
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
May 2nd 2024
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
April 30th 2024
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.
April 19th 2024
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
April 16th 2024
Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.
April 15th 2024
Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.
Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
April 13th 2024
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
April 11th 2024
The National Institute for Health and Care Excellence has recommended the use of tisagenlecleucel in pediatric B-cell acute lymphoblastic leukemia.
April 10th 2024
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
March 25th 2024
The FDA issued complete response letters to the BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
March 18th 2024
The FDA has accepted the resubmission of the BLA seeking the approval of denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma.
March 12th 2024
Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.
March 11th 2024
The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies
March 7th 2024
The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for select patients with relapsed/refractory follicular lymphoma.
March 6th 2024
Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.
February 24th 2024
Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.